Understanding how protein breakdown affects Alzheimer's disease
Proteasome function in Alzheimer's Disease
This study is looking at how a part of our cells that helps break down damaged proteins might be affected in Alzheimer's disease, and it aims to find ways to make this system work better to support brain health for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10837756 on NIH RePORTER |
What this research studies
This research investigates the role of the proteasome, a cellular system responsible for degrading misfolded proteins, in Alzheimer's disease (AD). It aims to understand how certain proteins, like Amyloid β and Tau, accumulate and inhibit the proteasome's function, potentially leading to neuronal dysfunction. The researchers will explore the mechanisms of this inhibition and develop proteasomes that can resist these harmful effects. By using both cellular and animal models, the study seeks to determine if enhancing proteasome activity can improve neuronal health in the context of AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance protein degradation in Alzheimer's patients, potentially slowing disease progression.
How similar studies have performed: Previous research has shown promising results in targeting protein degradation pathways in neurodegenerative diseases, suggesting that this approach could be effective.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Smith, David Matthew — West Virginia University
- Study coordinator: Smith, David Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.